Home LiteratureArticle Details
PMID: 25865224 Published · ppublish English Journal Article

Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.

Oncotarget ·Vol. 6 ·No. 11 ·2015-04-20 ·Pages 9542-50

Jiang L, Jiang S, Situ D, Lin Y, Yang H, Li Y, Long H, Zhou Z

Abstract

Metastatic soft tissue sarcomas (STS) represent enormous challenges to improve the low survival rate, which is almost the same as past 2 decades ago. Prognosis of cancer patients are based not only on tumor-related factors but also on host-related factors, particularly systemic inflammatory response. We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience. We found that both monocyte ratio and NLR ratio were significant prognostic predictors for OS and PFS of metastatic STS. And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up. For this reason, this result could serve as a basis for future prospective study.

Keywords
immunity metastasis prognosis soft tissue sarcoma
MeSH Terms
Adolescent Adult Aged Blood Cell Count Child Child, Preschool Disease-Free Survival Female Humans Kaplan-Meier Estimate Lymphocyte Count Male Middle Aged Monocytes Neutrophils Prognosis Retrospective Studies Risk Factors Sarcoma/blood,mortality,secondary,therapy Young Adult
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Jiang Long
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China. | University of California, San Francisco, CA, USA.
Jiang Shanshan
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Situ Dongrong
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Lin Yongbin
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Yang Han
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Li Yuanfang
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Long Hao
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
Zhou Zhiwei
Sun Yat-sen University Cancer Center, Guangzhou, China. | Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. | State Key Laboratory of Oncology in South China, Guangzhou, China.
References (55)
55 references, click to expand
  1. Secreted heat shock protein gp96-Ig: an innovative vaccine approach.
    Am J Reprod Immunol. 2008 May;59(5):407-16 PMID: 18405311
  2. CTLA-4 blockade: unveiling immune regulation.
    J Clin Oncol. 2005 Feb 1;23(4):662-4 PMID: 15613692
  3. [A case of retroperitoneal angiosarcoma effectively treated with recombinant interleukin-2].
    Nihon Hinyokika Gakkai Zasshi. 2012 Nov;103(6):697-703 PMID: 24261193
  4. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report.
    Cancer Med. 2014 Oct;3(5):1404-15 PMID: 25044961
  5. Ewing's sarcoma: standard and experimental treatment options.
    Curr Treat Options Oncol. 2009 Apr;10(1-2):126-40 PMID: 19533369
  6. GM-CSF-based cancer vaccines.
    Immunol Rev. 2002 Oct;188:147-54 PMID: 12445288
  7. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.
    J Immunol. 2002 Apr 1;168(7):3536-42 PMID: 11907116
  8. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.
    World J Surg. 2008 Aug;32(8):1757-62 PMID: 18340479
  9. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma.
    Surgery. 2006 Jun;139(6):755-64 PMID: 16782430
  10. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis.
    J Cell Physiol. 2001 Nov;189(2):197-206 PMID: 11598905
  11. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes.
    J Immunol. 1985 Jan;134(1):230-4 PMID: 3871101
  12. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system.
    J Immunol. 1987 Oct 1;139(7):2406-13 PMID: 2821114
  13. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.
    Sarcoma. 2013;2013:168145 PMID: 23554566
  14. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  15. Significance of increased neutrophils in patients with advanced colorectal cancer.
    Acta Oncol. 1995;34(1):69-73 PMID: 7532422
  16. Suppression of lymphokine-activated killer induction by neutrophils.
    J Immunol. 1988 Dec 15;141(12):4395-402 PMID: 3264311
  17. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
    Cancer Immunol Immunother. 2009 Jan;58(1):15-23 PMID: 18414853
  18. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  19. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.
    J Clin Oncol. 1999 Dec;17(12):3706-19 PMID: 10577842
  20. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma.
    Chin J Cancer. 2011 Apr;30(4):280-6 PMID: 21439250
  21. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    J Clin Oncol. 2011 Mar 1;29(7):917-24 PMID: 21282551
  22. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages.
    Cancer Lett. 2009 Apr 8;276(1):38-46 PMID: 19041175
  23. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.
    J Surg Oncol. 2005 Sep 1;91(3):181-4 PMID: 16118772
  24. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
    Oncology. 2007;73(3-4):215-20 PMID: 18424885
  25. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study.
    BMC Cancer. 2001;1:7 PMID: 11481031
  26. Results of thoracotomy in osteogenic sarcoma with pulmonary metastases.
    Thorax. 1991 Oct;46(10):727-31 PMID: 1750020
  27. Immunotherapy in sarcoma: a new frontier.
    Discov Med. 2014 Apr;17(94):201-6 PMID: 24759624
  28. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group.
    J Clin Oncol. 2000 Sep;18(17):3108-14 PMID: 10963639
  29. Tumor-associated macrophage (TAM) infiltration in gastric cancer.
    Anticancer Res. 2003 Sep-Oct;23(5A):4079-83 PMID: 14666722
  30. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
    J Clin Oncol. 2004 Dec 1;22(23):4787-94 PMID: 15570080
  31. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study.
    J Clin Oncol. 2002 Aug 15;20(16):3470-7 PMID: 12177108
  32. II. Contribution to the Knowledge of Sarcoma.
    Ann Surg. 1891 Sep;14(3):199-220 PMID: 17859590
  33. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity.
    J Immunol. 2012 Apr 1;188(7):3080-7 PMID: 22379028
  34. Human defensins as cancer biomarkers and antitumour molecules.
    J Proteomics. 2009 Aug 20;72(6):918-27 PMID: 19186224
  35. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
    J Clin Oncol. 2003 Jan 1;21(1):78-84 PMID: 12506174
  36. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.
    Future Oncol. 2010 Jan;6(1):149-63 PMID: 20021215
  37. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection.
    J Gastrointest Surg. 2007 May;11(5):596-602 PMID: 17468918
  38. Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report.
    Oncol Lett. 2013 May;5(5):1457-1460 PMID: 23761810
  39. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
    Cancer Sci. 2013 Oct;104(10):1285-94 PMID: 23829867
  40. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
    J Pediatr Surg. 2005 Jan;40(1):256-62 PMID: 15868594
  41. Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach.
    JAMA. 1982 Feb 19;247(7):1004-6 PMID: 7035703
  42. Cancer statistics, 2014.
    CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 PMID: 24399786
  43. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma.
    Clin Exp Immunol. 2010 Sep;161(3):471-9 PMID: 20636398
  44. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2009 Feb;137(2):425-8 PMID: 19185164
  45. The Third Intergroup Rhabdomyosarcoma Study.
    J Clin Oncol. 1995 Mar;13(3):610-30 PMID: 7884423
  46. Resection of recurrent pulmonary metastases in patients with osteosarcoma.
    Cancer. 2005 Oct 15;104(8):1721-5 PMID: 16155943
  47. Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck.
    Am J Surg. 1986 Nov;152(5):487-90 PMID: 3777326
  48. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
    Med Pediatr Oncol. 2002 Mar;38(3):158-64 PMID: 11836714
  49. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future.
    Curr Opin Oncol. 2008 Jul;20(4):412-8 PMID: 18525337
  50. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.
    Cancer Cell. 2006 Aug;10(2):99-111 PMID: 16904609
  51. WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary.
    Curr Opin Oncol. 2013 Sep;25(5):571-3 PMID: 23942303
  52. Systemic inflammation, nutritional status and survival in patients with cancer.
    Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6 PMID: 19318937
  53. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases.
    Eur J Surg Oncol. 2008 Jan;34(1):55-60 PMID: 17448623
  54. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer.
    Br J Surg. 2007 Aug;94(8):1028-32 PMID: 17437250
  55. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    J Clin Oncol. 2005 Jan 20;23(3):559-68 PMID: 15659502
Article Info
Journal
Oncotarget
Abbr.
Oncotarget
ISSN
1949-2553
DOI
10.18632/oncotarget.3283
Published
2015-04-20
Pages
9542-50
Language
English
Region
United States
NLM ID
101532965
PMCID
PMC4496237
Subset
IM
External Links
PubMed source DOI: 10.18632/oncotarget.3283 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2